1 min read
Add as a preferred source on Google

Recursion Aligns With FDA on Late-Stage Trial Design for REC-4881

Recursion described the program as an early example of AI-assisted drug discovery pursuing a design intended to support registration.

A single capsule rests on an examination table in an empty clinic. / TokenPost.ai
A single capsule rests on an examination table in an empty clinic. / TokenPost.ai

Recursion Pharmaceuticals said Nov. 18 that it aligned with the FDA on a late-stage trial design for REC-4881, a rare-disease therapy candidate.

Recursion described REC-4881 as an early example of AI-assisted drug discovery advancing toward a trial design intended to support registration.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…